Gynaecological Diagnostic Outpatient Treatment Unit, University College Hospital, London, UK.
Department of Statistical Science, University College London, London, UK.
Ultrasound Obstet Gynecol. 2018 Jun;51(6):829-835. doi: 10.1002/uog.18918. Epub 2018 Jun 4.
To determine whether International Ovarian Tumor Analysis (IOTA) logistic regression models LR1 and LR2 developed for the preoperative diagnosis of ovarian cancer could also be used to differentiate between benign and malignant adnexal tumors in the population of women attending gynecology outpatient clinics.
This was a single-center prospective observational study of consecutive women attending our gynecological diagnostic outpatient unit, recruited between May 2009 and January 2012. All the women were first examined by a Level-II ultrasound operator. In those diagnosed with adnexal tumors, the IOTA-LR1/2 protocol was used to evaluate the masses. The LR1 and LR2 models were then used to assess the risk of malignancy. Subsequently, the women were also examined by a Level-III examiner, who used pattern recognition to differentiate between benign and malignant tumors. Women with an ultrasound diagnosis of malignancy were offered surgery, while asymptomatic women with presumed benign lesions were offered conservative management with a minimum follow-up of 12 months. The initial diagnosis was compared with two reference standards: histological findings and/or a comparative assessment of tumor morphology on follow-up ultrasound scans. All women for whom the tumor classification on follow-up changed from benign to malignant were offered surgery.
In the final analysis, 489 women who had either or both of the reference standards were included. Their mean age was 50 years (range, 16-91 years) and 45% were postmenopausal. Of the included women, 342/489 (69.9%) had surgery and 147/489 (30.1%) were managed conservatively. The malignancy rate was 137/489 (28.0%). Overall, sensitivities of LR1 and LR2 for the diagnosis of malignancy were 97.1% (95% CI, 92.7-99.2%) and 94.9% (95% CI, 89.8-97.9%) and specificities were 77.3% (95% CI, 72.5-81.5%) and 76.7% (95% CI, 71.9-81.0%), respectively (P > 0.05). In comparison with pattern recognition (sensitivity 94.2% (95% CI, 88.8-97.4%), specificity 96.3% (95% CI, 93.8-98.0%)), the specificities of the IOTA models were significantly lower (P < 0.0001). A significantly higher number of women would have been offered surgery for suspected cancer if the women had been assessed using the IOTA models instead of pattern recognition (213/489 (43.6%) vs 142/489 (29.0%); P < 0.001).
The IOTA models maintained their high sensitivity when used in an outpatient setting. Specificity was relatively low, which indicates that a significant proportion of the women would have been offered unnecessary surgery for suspected ovarian cancer. These findings show that the IOTA models could be used as a first-stage test to diagnose ovarian cancer in an outpatient setting, but a different second-stage test is required to minimize the number of false-positive findings. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
确定国际卵巢肿瘤分析(IOTA)逻辑回归模型 LR1 和 LR2 是否也可用于区分妇科门诊就诊的女性的良性和恶性附件肿瘤。
这是一项单中心前瞻性观察性研究,连续纳入 2009 年 5 月至 2012 年 1 月在我院妇科诊断门诊就诊的女性。所有女性均首先由二级超声操作员进行检查。对于诊断为附件肿瘤的患者,采用 IOTA-LR1/2 方案评估肿块。然后使用 LR1 和 LR2 模型评估恶性肿瘤的风险。随后,由三级检查者进行检查,使用模式识别来区分良性和恶性肿瘤。超声诊断为恶性肿瘤的女性被建议手术,而无症状的疑似良性病变的女性则接受保守治疗,至少随访 12 个月。初始诊断与两个参考标准进行比较:组织学发现和/或随访超声扫描的肿瘤形态比较评估。所有肿瘤分类在随访中从良性变为恶性的女性均被建议手术。
最终分析纳入了 489 名具有任何一种参考标准或两种参考标准的女性。她们的平均年龄为 50 岁(范围 16-91 岁),45%为绝经后女性。在纳入的女性中,342/489(69.9%)接受了手术,147/489(30.1%)接受了保守治疗。恶性肿瘤发生率为 137/489(28.0%)。总体而言,LR1 和 LR2 诊断恶性肿瘤的敏感度分别为 97.1%(95%CI,92.7-99.2%)和 94.9%(95%CI,89.8-97.9%),特异性分别为 77.3%(95%CI,72.5-81.5%)和 76.7%(95%CI,71.9-81.0%)(P>0.05)。与模式识别(敏感度 94.2%(95%CI,88.8-97.4%),特异性 96.3%(95%CI,93.8-98.0%))相比,IOTA 模型的特异性显著较低(P<0.0001)。如果使用 IOTA 模型而不是模式识别来评估女性,将有更多的女性被建议手术治疗疑似癌症(213/489(43.6%)vs 142/489(29.0%);P<0.001)。
IOTA 模型在门诊环境中保持了较高的敏感度。特异性相对较低,这表明很大一部分女性将被建议进行不必要的疑似卵巢癌手术。这些发现表明,IOTA 模型可用作门诊诊断卵巢癌的第一阶段测试,但需要使用不同的第二阶段测试来减少假阳性发现的数量。版权所有©2017ISUOG。由 John Wiley & Sons Ltd 出版。